2026 Global: Micro-Invasive Glaucoma Implants Market -Competitive Review (2032) report
Description
The 2026 Global: Micro-Invasive Glaucoma Implants Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
The micro-invasive glaucoma implants market is led by a group of multinational device developers that have positioned MIGS as a core therapeutic option. Glaukos Corporation (San Clemente, United States) pioneered trabecular bypass stents with the iStent family, including iStent and iStent Inject, devices designed to augment aqueous outflow through Schlemm’s canal with minimal tissue disruption. Irvine, California–based Ivantis, Inc. introduced the Hydrus Microstent, a curved implant positioned in the Schlemm’s canal to enlarge its drainage pathway and reduce intraocular pressure. AbbVie, headquartered in North Chicago, United States, includes Allergan’s Xen Gel Stent portfolio, a small gelatinous tube implanted ab interno to create a controlled outflow channel to the subconjunctival space. Santen Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, markets the Preserflo MicroShunt, a minimally invasive tube intended to divert aqueous humor with less disruption to ocular tissues. Sight Sciences, Inc. (Menlo Park, California, United States) focuses on the OMNI Surgical System, enabling ab interno canaloplasty and trabeculotomy to modulate outflow without a filtration bleb.
Alcon, headquartered in Geneva, Switzerland, participates in MIGS through devices and surgical systems that complement ab interno approaches, including historical CyPass Micro-Stent and supportive instrumentation, although CyPass was withdrawn from the market in 2018. Nova Eye Medical Limited (Melbourne, Australia) develops and distributes iTrack microcatheters used in canaloplasty- and Schlemm’s canal–based MIGS procedures, expanding global access to microcatheter-assisted outflow strategies. New World Medical, Inc. (Fountain Valley, United States) markets the Kahook Dual Blade and related canal-based tools that enable safe goniotomy and trabeculotomy as components of MIGS workflows. iSTAR Medical (Paris, France) designs and develops novel micro-invasive glaucoma implants and delivery systems intended to facilitate controlled outflow with reduced tissue trauma. DORC International B.V. (Eindhoven, Netherlands) supplies ophthalmic surgical devices and ancillary instruments for MIGS, supporting ab interno catheter- and blade-based approaches.
Together, these ten companies anchor a growing, globally distributed market in micro-invasive glaucoma implants. The geographic breadth—North America, Europe, and Asia–Pacific—reflects divergent regulatory pathways, reimbursement environments, and surgeon training ecosystems that shape device adoption. Innovation tends to cluster around trabecular bypass, canal-based approaches, and minimally disruptive ab interno techniques that preserve conjunctival integrity while aiming for durable intraocular pressure reduction. The competition among Glaukos, Ivantis, AbbVie, Santen, Sight Sciences, Alcon, Nova Eye Medical, New World Medical, iSTAR Medical, and DORC International accelerates device sequencing, delivery systems, and compatibility with adjunctive therapies. Market leaders pursue longer-lasting efficacy, simplified implantation, and safety across diverse patient populations, including those with varying severities of glaucoma and comorbidities. As regulatory agencies review new MIGS devices and post-market surveillance expands safety databases, the role of training and surgeon experience remains central to outcomes. The trajectory suggests continued consolidation, broader indications, sustaining strong growth for these ten companies worldwide, sustainable outcomes.
The micro-invasive glaucoma implants market is led by a group of multinational device developers that have positioned MIGS as a core therapeutic option. Glaukos Corporation (San Clemente, United States) pioneered trabecular bypass stents with the iStent family, including iStent and iStent Inject, devices designed to augment aqueous outflow through Schlemm’s canal with minimal tissue disruption. Irvine, California–based Ivantis, Inc. introduced the Hydrus Microstent, a curved implant positioned in the Schlemm’s canal to enlarge its drainage pathway and reduce intraocular pressure. AbbVie, headquartered in North Chicago, United States, includes Allergan’s Xen Gel Stent portfolio, a small gelatinous tube implanted ab interno to create a controlled outflow channel to the subconjunctival space. Santen Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, markets the Preserflo MicroShunt, a minimally invasive tube intended to divert aqueous humor with less disruption to ocular tissues. Sight Sciences, Inc. (Menlo Park, California, United States) focuses on the OMNI Surgical System, enabling ab interno canaloplasty and trabeculotomy to modulate outflow without a filtration bleb.
Alcon, headquartered in Geneva, Switzerland, participates in MIGS through devices and surgical systems that complement ab interno approaches, including historical CyPass Micro-Stent and supportive instrumentation, although CyPass was withdrawn from the market in 2018. Nova Eye Medical Limited (Melbourne, Australia) develops and distributes iTrack microcatheters used in canaloplasty- and Schlemm’s canal–based MIGS procedures, expanding global access to microcatheter-assisted outflow strategies. New World Medical, Inc. (Fountain Valley, United States) markets the Kahook Dual Blade and related canal-based tools that enable safe goniotomy and trabeculotomy as components of MIGS workflows. iSTAR Medical (Paris, France) designs and develops novel micro-invasive glaucoma implants and delivery systems intended to facilitate controlled outflow with reduced tissue trauma. DORC International B.V. (Eindhoven, Netherlands) supplies ophthalmic surgical devices and ancillary instruments for MIGS, supporting ab interno catheter- and blade-based approaches.
Together, these ten companies anchor a growing, globally distributed market in micro-invasive glaucoma implants. The geographic breadth—North America, Europe, and Asia–Pacific—reflects divergent regulatory pathways, reimbursement environments, and surgeon training ecosystems that shape device adoption. Innovation tends to cluster around trabecular bypass, canal-based approaches, and minimally disruptive ab interno techniques that preserve conjunctival integrity while aiming for durable intraocular pressure reduction. The competition among Glaukos, Ivantis, AbbVie, Santen, Sight Sciences, Alcon, Nova Eye Medical, New World Medical, iSTAR Medical, and DORC International accelerates device sequencing, delivery systems, and compatibility with adjunctive therapies. Market leaders pursue longer-lasting efficacy, simplified implantation, and safety across diverse patient populations, including those with varying severities of glaucoma and comorbidities. As regulatory agencies review new MIGS devices and post-market surveillance expands safety databases, the role of training and surgeon experience remains central to outcomes. The trajectory suggests continued consolidation, broader indications, sustaining strong growth for these ten companies worldwide, sustainable outcomes.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
